.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,686,592

« Back to Dashboard

Details for Patent: 5,686,592

Title: High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
Abstract:This invention discloses high-affinity oligonucleotide ligands to human Immunoglobulin E (IgE), specifically RNA and ssDNA ligands having the ability to bind to IgE, and the methods for obtaining such ligands. The ligands are capable of inhibiting the interaction of IgE with its receptor.
Inventor(s): Wiegand; Torsten Walter (Boulder, CO), Tasset; Diane (Boulder, CO), Gold; Larry (Boulder, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Jun 06, 1995
Application Number:08/471,985
Claims:1. A nucleic acid ligand to the F.sub.c portion of IgE identified according to the method comprising:

a) preparing a candidate mixture of nucleic acids;

b) contacting said candidate mixture of nucleic acids with IgE, wherein nucleic acids having an increased affinity to IgE relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and

d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to IgE, whereby a nucleic acid ligand to IgE may be identified.

2. The nucleic acid ligand of claim 1 wherein said nucleic acid ligand comprises 2'-amino (2'-NH.sub.2) modified ribonucleic acids.

3. A purified and isolated non-naturally occurring RNA ligand to IgE wherein said ligand is selected from the group consisting of the sequences set forth in Table 1.

4. A purified and isolated non-naturally occurring RNA ligand to IgE comprising the sequences selected from the group consisting of SEQ ID NOS: 45 and 46.

5. The ligand of claim 4 comprising the sequence of SEQ ID NO:45.

6. A purified and isolated non-naturally occurring DNA ligand to IgE wherein said ligand is selected from the group consisting of the sequences set forth in Tables 5 and 6.

7. A purified and isolated non-naturally occurring nucleic acid ligand to the F.sub.c portion of IgE.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc